Cerebras
CBRS
$230.01
+1.45%
Cerebras Systems Inc. is an AI company that designs and builds the world's largest semiconductor chips and AI supercomputers for training and inference, targeting the high-performance AI infrastructure market. As a niche player challenging Nvidia's dominance, Cerebras differentiates itself with its wafer-scale engine technology and software that integrates with PyTorch, offering a compelling alternative for AI workloads. The company recently went public in May 2026, and the stock has been highly volatile, driven by massive revenue growth, a $25 billion backlog, and partnerships with OpenAI and AWS, but tempered by concerns over valuation, gross margin guidance, and the path to profitability. The current investor narrative centers on whether Cerebras can sustain its explosive growth and capture meaningful market share in the AI chip race, despite intense competition and a rich valuation.…
CBRS
Cerebras
$230.01
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. The consensus is 'Strong Buy' with an average target of $292, implying 38.2% upside, but the extreme valuation and volatility warrant caution. The thesis is that Cerebras has exceptional growth potential, but the current price already reflects high expectations, limiting near-term upside.
Sign up to view all
CBRS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the company's growth metrics are impressive, the valuation is stretched, and the stock's price action suggests caution. The key is whether Cerebras can sustain its growth trajectory and improve profitability. If revenue growth accelerates and margins expand, the stance could upgrade to bullish; if growth decelerates or losses widen, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $292.00 and implied upside of +26.9% versus the current price.
Average Target
$292.00
0 analysts
Implied Upside
+26.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $340
Analyst target range
Cerebras has coverage from 11 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.45 (where 1 is Strong Buy and 5 is Sell). The average target price is $292.00, which implies an upside of 38.2% from the current price of $211.30. The target range is $209.00 to $340.00, with the low target slightly below the current price, indicating some bearish risk. The high target of $340.00 suggests that analysts see significant upside potential, likely driven by the company's revenue growth and backlog. Recent ratings from firms like Rosenblatt, UBS, Wedbush, Morgan Stanley, and Needham have all been positive, with no downgrades, indicating a bullish sentiment. However, the wide spread between the low and high targets (63% difference) reflects high uncertainty about the company's future, typical for a newly listed, high-growth AI stock.
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a classic high-growth, high-risk investment. The bull case is anchored by exceptional revenue growth, a massive backlog, and improving margins, while the bear case centers on an extreme valuation, ongoing losses, and intense competition. Currently, the bearish evidence is stronger given the stock's downtrend and the market's pricing of perfection. The most critical tension is whether Cerebras can convert its backlog into profitable, sustainable growth—if it does, the stock could re-rate higher; if not, the valuation could compress sharply. Investors must weigh the potential for outsized returns against the significant risk of a continued decline.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 94.35% YoY to $193.4M, with sequential growth of 12.8% from Q4 2025. This rapid acceleration demonstrates strong market demand for AI infrastructure, supported by a $25B backlog and partnerships with OpenAI and AWS.
- Massive Backlog and Key Partnerships: The $25B backlog provides multi-year revenue visibility, while strategic deals with OpenAI and AWS validate the technology and secure future growth. These relationships are critical for scaling and market penetration.
- Improving Gross Margins: Gross margin improved to 44.6% in Q1 2026, up from 31.1% in Q2 2025, indicating better cost management and operating leverage. This trend is essential for achieving profitability and justifies the premium valuation.
- Strong Analyst Consensus: With 11 analysts, the consensus is 'Strong Buy' (mean rating 1.45) and an average target price of $292, implying 38.2% upside from the current price of $211.30. No downgrades have been issued, reflecting positive sentiment.
Bearish
- Extreme Valuation Premium: The trailing PS ratio is 131.3x, and even forward PS is 32.3x, versus the semiconductor industry average of ~10x. This implies the market is pricing in flawless execution and massive growth, leaving little room for error.
- Persistent Unprofitability: Despite revenue growth, the company reported a net loss of $14.0M in Q1 2026, and operating margin was -7.8%. While losses are narrowing, the path to sustained profitability remains uncertain, especially with heavy R&D spending.
- Negative Equity and High Debt: The debt-to-equity ratio is -0.45, indicating negative shareholders' equity due to accumulated losses. This financial structure could limit future borrowing capacity and increase financial risk if cash reserves deplete.
- High Volatility and Downward Trend: Since the IPO, the stock has fallen ~32% from its first close, with a max drawdown of -45.83%. The stock trades near the lower end of its 52-week range, reflecting bearish momentum and investor uncertainty.
CBRS Technical Analysis
Cerebras has been in a pronounced downtrend since its IPO on May 14, 2026, when it closed at $311.07, and has since fallen to $211.30 as of August 6, 2026, a decline of approximately 32% from its first close. The stock is currently trading at 54.7% of its 52-week range (between $160.81 low and $386.34 high), indicating it is closer to the lows than the highs, which suggests a bearish or corrective phase. The 1-year price change is not available since the stock is newly listed, but the price action since listing shows a clear downward trajectory, with the stock making lower highs and lower lows.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | +2.4% |
| 3m | — | +4.7% |
| 6m | — | +11.7% |
| 1y | — | +21.3% |
| ytd | — | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Cerebras has demonstrated exceptional revenue growth, with Q1 2026 revenue of $193.4 million, up 94.35% year-over-year from $99.5 million in Q1 2025. The sequential growth is also strong, with revenue increasing from $171.4 million in Q4 2025 to $193.4 million in Q1 2026, a 12.8% quarter-over-quarter increase. This growth is driven by strong demand for AI infrastructure, as evidenced by the company's $25 billion backlog and partnerships with OpenAI and AWS. However, the company is still unprofitable, with a net loss of $14.0 million in Q1 2026, though this is a significant improvement from the $105.7 million loss in Q4 2024. Gross margin has been improving, reaching 44.6% in Q1 2026, up from 31.1% in Q2 2025, indicating better cost management and scale. The balance sheet shows a current ratio of 2.15, indicating good short-term liquidity, but the debt-to-equity ratio is negative at -0.45, which is unusual and may indicate negative equity due to accumulated losses. Free cash flow was negative at -$119.6 million in Q1 2026, but the company raised significant capital through its IPO, ending the quarter with $2.75 billion in cash.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given that Cerebras has negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and it stands at 131.3x trailing, which is extremely high. The forward PS ratio, based on estimated revenue of $7.36 billion for the next year, would be approximately 32.3x, implying the market expects massive revenue growth to justify the valuation. Compared to the semiconductor industry average PS ratio of around 10x, Cerebras trades at a significant premium, reflecting its high growth potential but also pricing in perfection. Historically, the PS ratio has been even higher, with a peak of 981.7x in Q1 2024, so the current multiple is actually lower than its historical average, suggesting some de-rating but still at extreme levels. The EV/Sales ratio of 88.65x further underscores the rich valuation, and the PEG ratio is negative due to negative earnings, making it unhelpful.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company is unprofitable, with a net loss of $14.0M in Q1 2026, and negative free cash flow of -$119.6M, indicating cash burn. Although it holds $2.75B in cash, the negative equity (debt-to-equity -0.45) and high R&D spending (75.5% of revenue) could strain finances if growth stalls. Revenue concentration is also a concern, as a few large customers like OpenAI and AWS account for a significant portion of sales, making the company vulnerable to contract renegotiations or cancellations.
FAQ
The key risks are: 1) Valuation risk - the stock trades at 131x sales, leaving little room for error; 2) Financial risk - the company is unprofitable with negative equity and cash burn, though it has a large cash buffer; 3) Competitive risk - Nvidia's dominance could limit market share gains; 4) Execution risk - any delays or contract losses could severely impact growth. The most severe risk is a combination of these factors leading to a de-rating and a drop to the 52-week low of $160.81, a 24% downside from current levels.
The 12-month forecast is mixed. In the base case (50% probability), the stock could reach the analyst average target of $292, a 38% gain. In the bull case (25% probability), it could hit $340, a 61% gain, if growth accelerates. In the bear case (25% probability), it could fall to $160, a 24% loss, if execution falters. The most likely scenario is the base case, assuming continued revenue growth and stable margins. However, the high volatility and uncertainty make any forecast highly speculative.
CBRS is significantly overvalued based on traditional metrics. The trailing PS ratio of 131.3x is far above the semiconductor industry average of ~10x, and even the forward PS of 32.3x implies the market expects massive revenue growth. The EV/Sales ratio of 88.65x further confirms the premium. This valuation suggests the market is pricing in near-perfect execution and a dominant market position, which is highly optimistic given the competitive landscape. The stock is not undervalued by any conventional measure.
CBRS is a good buy only for investors with a high risk tolerance and a long-term perspective. The stock offers significant upside potential, with analysts targeting a 38.2% gain, but it also carries substantial downside risk, as evidenced by its 32% decline since IPO. The extreme valuation (PS ratio of 131x) means any misstep could lead to sharp losses. For conservative investors, it's better to wait for more clarity on profitability and valuation. For aggressive investors, it could be a speculative addition to a diversified portfolio.
CBRS is better suited for long-term investment, given its high volatility and early-stage growth. The stock has a beta that is likely high, and its price swings are extreme, making it unsuitable for short-term trading unless one has a high risk appetite. The company's growth story, backed by a $25B backlog, suggests that a holding period of at least 3-5 years could allow the business to mature and the valuation to normalize. Short-term traders may find opportunities, but the risk of significant losses is elevated. For most investors, a long-term horizon is recommended to ride out volatility and capture potential upside.